Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RYZ101 Dose Level 1
RYZ101 · 3 trials · 12 indications
| Name | Type | Description |
|---|---|---|
| RYZ101 | DRUG | RP3D as determined in Phase 1b |
| Everolimus | DRUG | Everolimus |
| Sunitinib | DRUG | Sunitinib |
| Octreotide | DRUG | High-dose octreotide |
| Lanreotide | DRUG | Lanreotide |
| RYZ101 Dose Level 1 | DRUG | Dose Level 1 |
| RYZ101 Dose Level 2 | DRUG | Dose Level 2 |
| RYZ101 Dose Level 3 | DRUG | Dose Level 3 |
| RYZ101 Dose Level -1 | DRUG | Dose Level -1 |
| Atezolizumab | DRUG | Atezolizumab |
| Carboplatin | DRUG | Carboplatin |
| Etoposide | DRUG | Etoposide |
RYZ101 is an investigational oncology therapy being studied in gastroenteropancreatic neuroendocrine tumors (GEP-NET), ER-positive HER2-negative metastatic breast cancer, and extensive-stage small cell lung cancer. It is being developed by Bristol-Myers Squibb Company (BMY) and holds an orphan drug designation from the FDA.
RYZ101 is a small molecule that targets somatostatin receptors (SSTRs). It is designed to deliver radiation to SSTR-expressing tumors. The trials enroll patients whose tumors express SSTRs, including SSTR-positive GEP-NET and SSTR-positive extensive-stage small cell lung cancer.
RYZ101 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company is running clinical trials of RYZ101 in GEP-NET, metastatic breast cancer, and extensive-stage small cell lung cancer.
RYZ101 is in Phase 3 development. The Phase 3 trial is evaluating RYZ101 compared with standard of care in patients with inoperable SSTR-positive well-differentiated GEP-NET that has progressed following 177Lu-SSA therapy. RYZ101 is investigational and has not been approved by the FDA.
RYZ101 is being studied in three clinical trials. NCT05477576 is a Phase 3 trial in SSTR-positive well-differentiated GEP-NET. NCT05595460 is a Phase 1 trial in SSTR-positive extensive-stage small cell lung cancer. NCT06590857 is a Phase 1/2 trial in ER-positive HER2-negative metastatic breast cancer expressing SSTRs.
RYZ101 Dose Level 1 is an alternative name used for RYZ101. Both refer to the same investigational therapy developed by Bristol-Myers Squibb Company (BMY) for SSTR-expressing tumors, including GEP-NET, metastatic breast cancer, and extensive-stage small cell lung cancer.